Market Overview

MKM Partners On Activision Blizzard: Rolling Out The Big Guns In Q3

Share:

Eric Handler of MKM Partners previewed Activision Blizzard, Inc. (NASDAQ: ATVI) ahead of the company's third quarter results on Tuesday after market close.

"We remain positive towards Activision and continue to believe the company is well positioned to once again exceed quarterly estimates and the Street's full year outlook," Handler wrote in a note to clients on Tuesday.

Handler is projecting Activision to earn $0.12 per share in the third quarter on revenue of $1.0 billion. This compares to consensus estimates calling for the company to earn $0.13 per share on $1.005 billion in revenue. When Activision reported its second quarter results on August 5, the company guided its third quarter EPS to be $0.11 on revenue of $975 million.

Activision's "Destiny" should account for nearly half of total revenue in the third quarter, according to Handler's estimates. Despite expectations of strong sales, the analyst expects Activision's gross margins to fall to 65.0 percent from 74.3 percent last year, due to higher product and marketing costs associated with the launch of "Destiny."

Handler expects Activision to be "flush with cash" at the end of the year with plenty of flexibility to repurchase the remainder of Vivendi's 43.5 million shares, announce a new buyback plan or payback debt.

Shares are Buy rated with a $26 price target.

Latest Ratings for ATVI

DateFirmActionFromTo
Oct 2019MaintainsOverweight
Oct 2019MaintainsBuy
Oct 2019DowngradesMarket PerformUnderperform

View More Analyst Ratings for ATVI
View the Latest Analyst Ratings

Posted-In: Activision Blizzard Destiny Eric Handler MKM PartnersAnalyst Color Analyst Ratings

 

Related Articles (ATVI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SAHMorgan StanleyMaintains22.0
SCPLMorgan StanleyMaintains12.0
PRUMorgan StanleyMaintains108.0
PAGMorgan StanleyMaintains59.0
LADMorgan StanleyMaintains151.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

Shares of RGLS keep Moving Higher: Here is a primer we wrote on RGLS